{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:58:16Z","timestamp":1777895896643,"version":"3.51.4"},"reference-count":135,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.mayocp.2016.04.013","type":"journal-article","created":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T10:56:01Z","timestamp":1464778561000},"page":"770-786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["My Approach to the Patient With Familial Hypercholesterolemia"],"prefix":"10.1016","volume":"91","author":[{"given":"Maya S.","family":"Safarova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iftikhar J.","family":"Kullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.108.809970","article-title":"Evolutionary genetics of coronary heart disease","volume":"119","author":"Ding","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/FPC.0b013e3282f44d99","article-title":"Molecular population genetics of PCSK9: a signature of recent positive selection","volume":"18","author":"Ding","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"10.1016\/j.mayocp.2016.04.013_bib3","doi-asserted-by":"crossref","first-page":"e1098","DOI":"10.1371\/journal.pone.0001098","article-title":"Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species","volume":"2","author":"Ding","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.mayocp.2016.04.013_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.0954-6820.1938.tb19279.x","article-title":"Xanthomata, hypercholesterolemia, angina pectoris","volume":"89","author":"Muller","year":"1938","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.mayocp.2016.04.013_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archinte.1939.00190040016002","article-title":"Angina pectoris in hereditary xanthomatosis","volume":"64","author":"Muller","year":"1939","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mayocp.2016.04.013_bib6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0002-9343(64)90196-2","article-title":"The inheritance of essential familial hypercholesterolemia","volume":"37","author":"Khachadurian","year":"1964","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2016.04.013_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM196702022760507","article-title":"Fat transport in lipoproteins: an integrated approach to mechanisms and disorders","volume":"276","author":"Fredrickson","year":"1967","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2016.04.013_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"10.1016\/j.mayocp.2016.04.013_bib9","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1073\/pnas.80.24.7501","article-title":"cDNA cloning of the bovine low density lipoprotein receptor: feedback regulation of a receptor mRNA","volume":"80","author":"Russell","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.mayocp.2016.04.013_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/humu.22215","article-title":"Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation","volume":"34","author":"Marduel","year":"2013","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2013.09.007","article-title":"APOE p.Leu167del mutation in familial hypercholesterolemia","volume":"231","author":"Awan","year":"2013","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.mayocp.2016.04.013_bib13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1161\/01.ATV.14.10.1553","article-title":"Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: sex-specific effects","volume":"14","author":"Ferrieres","year":"1994","journal-title":"Arterioscler Thromb"},{"issue":"6","key":"10.1016\/j.mayocp.2016.04.013_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCRESAHA.115.304660","article-title":"Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia","volume":"115","author":"Fouchier","year":"2014","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ejhg.2015.100","article-title":"Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction","volume":"24","author":"Braenne","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"5520","key":"10.1016\/j.mayocp.2016.04.013_bib16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1060458","article-title":"Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein","volume":"292","author":"Garcia","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.mayocp.2016.04.013_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9874","key":"10.1016\/j.mayocp.2016.04.013_bib18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1373\/clinchem.2014.231365","article-title":"Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries","volume":"61","author":"Futema","year":"2015","journal-title":"Clin Chem"},{"issue":"8","key":"10.1016\/j.mayocp.2016.04.013_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jmedgenet-2014-102405","article-title":"Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR\/APOB\/PCSK9 mutations","volume":"51","author":"Futema","year":"2014","journal-title":"J\u00a0Med Genet"},{"issue":"32","key":"10.1016\/j.mayocp.2016.04.013_bib21","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management: a position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.mayocp.2016.04.013_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwh237","article-title":"Familial hypercholesterolemia and coronary heart disease: a HuGE association review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"45","key":"10.1016\/j.mayocp.2016.04.013_bib23","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"3, suppl","key":"10.1016\/j.mayocp.2016.04.013_bib24","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"issue":"7254","key":"10.1016\/j.mayocp.2016.04.013_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/bmj.321.7254.148","article-title":"Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study","volume":"321","author":"Neil","year":"2000","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.mayocp.2016.04.013_bib26","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.atherosclerosis.2014.12.034","article-title":"Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT)","volume":"238","author":"Weng","year":"2015","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.mayocp.2016.04.013_bib28","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.atherosclerosis.2014.11.015","article-title":"Prevalence and clinical correlates of familial hypercholesterolemia founder mutations in the general population","volume":"238","author":"Lahtinen","year":"2015","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.mayocp.2016.04.013_bib30","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1017\/S1368980009991868","article-title":"Iron intake and body iron stores, anaemia and risk of hyperglycaemia among Chinese adults: the prospective Jiangsu Nutrition Study (JIN)","volume":"13","author":"Shi","year":"2010","journal-title":"Public Health Nutr"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0168-8227(02)00025-6","article-title":"The Australian Diabetes, Obesity and Lifestyle Study (AusDiab): methods and response rates","volume":"57","author":"Dunstan","year":"2002","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.mayocp.2016.04.013_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2015.03.027","article-title":"Prevalence and treatment of familial hypercholesterolaemia in Australian communities","volume":"185","author":"Watts","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.mayocp.2016.04.013_bib33","unstructured":"The Medway Clinical Commissioning Group. Systematically Identifying Familial Hypercholesterolemia in Primary Care: Interim Report for HEART UK Conference, July 2-4 2014. Berkshire, United Kingdom: Heart UK; 2014:1-8."},{"issue":"19","key":"10.1016\/j.mayocp.2016.04.013_bib34","first-page":"5","article-title":"Consensus Statement of the Russian National Atherosclerosis Society. Familial hypercholesterolemia in Russia: outstanding issues in diagnosis and management [in Russian]. Ateroskleroz i dislipidemii","volume":"2","author":"Karpov","year":"2015"},{"issue":"5","key":"10.1016\/j.mayocp.2016.04.013_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jacl.2015.06.015","article-title":"Screening and advanced lipid phenotyping in familial hypercholesterolemia: the Very Large Database of Lipids Study-17 (VLDL-17)","volume":"9","author":"Miller","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/clc.22223","article-title":"Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice","volume":"37","author":"Foody","year":"2014","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib37","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ahj.2013.12.008","article-title":"Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry","volume":"167","author":"O'Brien","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.mayocp.2016.04.013_bib38","article-title":"Initial results from the CASCADE-FH registry: cascade screening for awareness and detection of familial hypercholesterolemia","volume":"65","author":"O'Brien","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mayocp.2016.04.013_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: Data from the CASCADE-FH Registry","author":"deGoma","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"De Backer","year":"2015","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.mayocp.2016.04.013_bib41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia, part 1: executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.04.013_bib42","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","article-title":"Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers","volume":"233","author":"Besseling","year":"2014","journal-title":"Atherosclerosis"},{"issue":"suppl","key":"10.1016\/j.mayocp.2016.04.013_bib44","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J\u00a0Lipid Res"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCGENETICS.111.962456","article-title":"Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH","volume":"5","author":"Huijgen","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"issue":"pt 2","key":"10.1016\/j.mayocp.2016.04.013_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1258\/acb.2007.007078","article-title":"Are patients with familial hypercholesterolaemia well managed in lipid clinics? an audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project","volume":"45","author":"Hadfield","year":"2008","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.ATV.18.2.309","article-title":"Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada","volume":"18","author":"Pimstone","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.04.013_bib48","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jacl.2015.07.005","article-title":"Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit","volume":"9","author":"Pang","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.mayocp.2016.04.013_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2015.07.022","article-title":"Peripheral arterial disease in heterozygous familial hypercholesterolemia","volume":"242","author":"Pereira","year":"2015","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.mayocp.2016.04.013_bib51","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/aje\/kwh238","article-title":"Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview","volume":"160","author":"Hutter","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.mayocp.2016.04.013_bib52","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1161\/01.ATV.0000183888.48105.d1","article-title":"The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias","volume":"25","author":"Junyent","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.atherosclerosis.2004.12.001","article-title":"The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population","volume":"180","author":"Damgaard","year":"2005","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib54","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/joim.12335","article-title":"Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia","volume":"278","author":"Vongpromek","year":"2015","journal-title":"J\u00a0Intern Med"},{"issue":"6","key":"10.1016\/j.mayocp.2016.04.013_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5551\/jat.13.323","article-title":"Cholesterol-years score is associated with development of senile degenerative aortic stenosis in heterozygous familial hypercholesterolemia","volume":"13","author":"Nozue","year":"2006","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"24","key":"10.1016\/j.mayocp.2016.04.013_bib56","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1016\/j.jacc.2015.09.087","article-title":"Increased aortic valve calcification in familial hypercholesterolemia: prevalence, extent, and associated risk factors","volume":"66","author":"ten Kate","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.mayocp.2016.04.013_bib57","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMra1313875","article-title":"Aortic-valve stenosis: from patients at risk to severe valve obstruction","volume":"371","author":"Otto","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocp.2016.04.013_bib58","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2015.03.003","article-title":"Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales","volume":"240","author":"Haralambos","year":"2015","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.mayocp.2016.04.013_bib60","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"10","key":"10.1016\/j.mayocp.2016.04.013_bib61","doi-asserted-by":"crossref","first-page":"75D","DOI":"10.1016\/0002-9149(93)90015-5","article-title":"Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications","volume":"72","author":"Goldman","year":"1993","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.04.013_bib62","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1515\/CCLM.2008.135","article-title":"Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing","volume":"46","author":"Starr","year":"2008","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"10.1016\/j.mayocp.2016.04.013_bib63","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/gim.2015.71","article-title":"Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement","volume":"18","author":"Medeiros","year":"2016","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib65","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12529-014-9402-x","article-title":"Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment","volume":"22","author":"Hardcastle","year":"2015","journal-title":"Int J Behav Med"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib66","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajmg.a.30102","article-title":"Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial","volume":"128A","author":"Marteau","year":"2004","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib67","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.ejhg.5201940","article-title":"Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance","volume":"16","author":"Homsma","year":"2008","journal-title":"Eur J Hum Genet"},{"issue":"7","key":"10.1016\/j.mayocp.2016.04.013_bib68","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ejhg.2012.5","article-title":"Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study","volume":"20","author":"Huijgen","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.mayocp.2016.04.013_bib69","unstructured":"Centers for Disease Control and Prevention. Genomics implementation. More detailed information on key tier 1 applications: familial hypercholesterolemia. http:\/\/www.cdc.gov\/genomics\/implementation\/toolkit\/fh_1.htm. Accessed October 5, 2015."},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2796.2003.01070.x","article-title":"Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia","volume":"253","author":"de Sauvage Nolting","year":"2003","journal-title":"J\u00a0Intern Med"},{"issue":"9","key":"10.1016\/j.mayocp.2016.04.013_bib71","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0022-2275(20)41918-2","article-title":"Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia","volume":"32","author":"Leitersdorf","year":"1991","journal-title":"J\u00a0Lipid Res"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib72","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"20","author":"Kraft","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib73","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1373\/clinchem.2010.154773","article-title":"Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population","volume":"57","author":"van Deventer","year":"2011","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.mayocp.2016.04.013_bib74","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.amjcard.2015.05.013","article-title":"Reliability of calculated low-density lipoprotein cholesterol","volume":"116","author":"Meeusen","year":"2015","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/j.mayocp.2016.04.013_bib75","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2006.11.039","article-title":"Arterial ultrasonography and tonometry as adjuncts to cardiovascular risk stratification","volume":"49","author":"Kullo","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.mayocp.2016.04.013_bib76","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/hrt.2010.220699","article-title":"CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia","volume":"97","author":"Neefjes","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.mayocp.2016.04.013_bib77","first-page":"1","article-title":"The use of CT coronary calcium score in asymptomatic patients with familial hypercholesterolaemia","volume":"5","author":"Shipman","year":"2015","journal-title":"Br J Diabetes Vasc Dis"},{"issue":"10","key":"10.1016\/j.mayocp.2016.04.013_bib78","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jama.2014.8892","article-title":"Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia","volume":"312","author":"Kusters","year":"2014","journal-title":"JAMA"},{"issue":"3 suppl","key":"10.1016\/j.mayocp.2016.04.013_bib79","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jacl.2011.03.451","article-title":"National Lipid Association Expert Panel on Familial Hypercholesterolemia. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Robinson","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib80","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/healthcare3030830","article-title":"Genomics in public health: perspective from the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC)","volume":"3","author":"Green","year":"2015","journal-title":"Healthcare (Basel)"},{"issue":"25, pt B","key":"10.1016\/j.mayocp.2016.04.013_bib81","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib82","first-page":"61","article-title":"Family history fails to identify many children with severe hypercholesterolemia","volume":"145","author":"Starc","year":"1991","journal-title":"Am J Dis Child"},{"issue":"11","key":"10.1016\/j.mayocp.2016.04.013_bib83","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jacc.2015.07.017","article-title":"Universal screening for familial hypercholesterolemia in children","volume":"66","author":"Klancar","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3, suppl","key":"10.1016\/j.mayocp.2016.04.013_bib84","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"issue":"7620","key":"10.1016\/j.mayocp.2016.04.013_bib85","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/bmj.39300.616076.55","article-title":"Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis","volume":"335","author":"Wald","year":"2007","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib86","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ncpcardio1084","article-title":"Screening for familial hypercholesterolemia: what is the most effective strategy?","volume":"5","author":"Daniels","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.mayocp.2016.04.013_bib87","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/CIRCOUTCOMES.114.000842","article-title":"Lipid screening in children and adolescents in community practice: 2007 to 2010","volume":"7","author":"Margolis","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"10.1016\/j.mayocp.2016.04.013_bib88","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jpeds.2011.06.006","article-title":"Child-parent screening for familial hypercholesterolemia","volume":"159","author":"Wald","year":"2011","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.mayocp.2016.04.013_bib89","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cca.2013.03.027","article-title":"Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia","volume":"422","author":"Bell","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"suppl 5","key":"10.1016\/j.mayocp.2016.04.013_bib90","first-page":"S213","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","year":"2011","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.mayocp.2016.04.013_bib91","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.ijcard.2013.01.280","article-title":"A\u00a0systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia","volume":"167","author":"Ademi","year":"2013","journal-title":"Int J Cardiol"},{"issue":"9251","key":"10.1016\/j.mayocp.2016.04.013_bib92","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands","volume":"357","author":"Umans-Eckenhausen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2016.04.013_bib93","series-title":"Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: The Identification and Management of Adults and Children With Familial Hypercholesterolaemia","author":"DeMott","year":"2008"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib94","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosissup.2011.06.001","article-title":"Familial hypercholesterolaemia: a model of care for Australasia","volume":"12","author":"Watts","year":"2011","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.mayocp.2016.04.013_bib95","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib96","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2015.09.029","article-title":"Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes","volume":"243","author":"Thompson","year":"2015","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib97","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MOL.0000000000000178","article-title":"A\u00a0comparison of European and US guidelines for familial hypercholesterolaemia","volume":"26","author":"Reiner","year":"2015","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"10.1016\/j.mayocp.2016.04.013_bib98","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cjca.2014.09.028","article-title":"Canadian Cardiovascular Society position statement on familial hypercholesterolemia","volume":"30","author":"Genest","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.mayocp.2016.04.013_bib99","unstructured":"National Institutet for Health and Care Excellence. Familial hypercholesterolaemia: identification and management. 2008. https:\/\/www.nice.org.uk\/guidance\/cg71. Accessed September 1, 2015."},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib100","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.atherosclerosis.2006.10.036","article-title":"Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients","volume":"194","author":"Pisciotta","year":"2007","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib101","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5551\/jat.1651","article-title":"Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia","volume":"17","author":"Nozue","year":"2010","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"8","key":"10.1016\/j.mayocp.2016.04.013_bib102","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib103","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacl.2011.01.005","article-title":"A\u00a0systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia","volume":"5","author":"Davidson","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib104","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J\u00a0Manag Care Pharm"},{"issue":"9","key":"10.1016\/j.mayocp.2016.04.013_bib105","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.mayocp.2016.04.013_bib106","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2016.04.013_bib107","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","author":"Visser","year":"2010","journal-title":"J\u00a0Lipid Res"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib108","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.atherosclerosis.2007.06.028","article-title":"A\u00a0dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia","volume":"197","author":"Marais","year":"2008","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.mayocp.2016.04.013_bib109","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression","volume":"61","author":"Lavigne","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib111","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ecl.2008.11.007","article-title":"Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety","volume":"38","author":"Hou","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"10.1016\/j.mayocp.2016.04.013_bib112","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2013.06.014","article-title":"The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients","volume":"35","author":"Davidson","year":"2013","journal-title":"Clin Ther"},{"issue":"43","key":"10.1016\/j.mayocp.2016.04.013_bib113","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"issue":"9965","key":"10.1016\/j.mayocp.2016.04.013_bib114","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"9965","key":"10.1016\/j.mayocp.2016.04.013_bib115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib116","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"issue":"9719","key":"10.1016\/j.mayocp.2016.04.013_bib117","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"9860","key":"10.1016\/j.mayocp.2016.04.013_bib118","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.mayocp.2016.04.013_bib119","first-page":"1377","article-title":"Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case: trial of plasmapheresis and heroic treatment","volume":"118","author":"de Gennes","year":"1967","journal-title":"Bull Mem Soc Med Hop Paris"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J\u00a0Clin Apher"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib121","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1399-3046.2010.01458.x","article-title":"Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late","volume":"15","author":"Malatack","year":"2011","journal-title":"Pediatr Transplant"},{"issue":"36","key":"10.1016\/j.mayocp.2016.04.013_bib122","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib123","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0021-9150(01)00765-1","article-title":"Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia","volume":"163","author":"Noji","year":"2002","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib124","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5551\/jat.28753","article-title":"Efficacy and safety of pitavastatin in Japanese male children with familial hypercholesterolemia","volume":"23","author":"Harada-Shiba","year":"2016","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mayocp.2016.04.013_bib126","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2015.02.043","article-title":"Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia","volume":"166","author":"Kusters","year":"2015","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib127","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpeds.2009.08.037","article-title":"Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia","volume":"156","author":"Stein","year":"2010","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1744-9987.2009.00666.x","article-title":"Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia","volume":"13","author":"Coker","year":"2009","journal-title":"Ther Apher Dial"},{"issue":"6","key":"10.1016\/j.mayocp.2016.04.013_bib129","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-3476(05)81956-0","article-title":"Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis","volume":"120","author":"Uauy","year":"1992","journal-title":"J\u00a0Pediatr"},{"issue":"5, pt 1","key":"10.1016\/j.mayocp.2016.04.013_bib130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0022-3476(95)70400-0","article-title":"Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia","volume":"126","author":"Zwiener","year":"1995","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.mayocp.2016.04.013_bib131","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1744-9987.2008.00574.x","article-title":"Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years","volume":"12","author":"Palcoux","year":"2008","journal-title":"Ther Apher Dial"},{"issue":"1","key":"10.1016\/j.mayocp.2016.04.013_bib132","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/s-0032-1305798","article-title":"Pregnancy in a woman with homozygous familial hypercholesterolemia not on low-density lipoprotein apheresis","volume":"2","author":"Fahed","year":"2012","journal-title":"AJP Rep"},{"issue":"15","key":"10.1016\/j.mayocp.2016.04.013_bib133","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.111.059311","article-title":"Maternal heterozygous familial hypercholesterolemia and its consequences for mother and child","volume":"124","author":"Rutherford","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.mayocp.2016.04.013_bib134","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/0026-0495(94)90061-2","article-title":"Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis","volume":"43","author":"Kroon","year":"1994","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.mayocp.2016.04.013_bib135","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.atherosclerosis.2015.10.012","article-title":"The impact of gestational hypercholesterolaemia on origins of disease","volume":"243","author":"Schofield","year":"2015","journal-title":"Atherosclerosis"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616301215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616301215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T08:00:54Z","timestamp":1718611254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619616301215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":135,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0025619616301215"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.04.013","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"My Approach to the Patient With Familial Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}